Kytril

Granisetron, the active ingredient in Kytril, is a selective 5‑HT3 receptor antagonist presented as an injectable solution for intravenous use. It is employed to prevent chemotherapy‑induced and postoperative nausea and vomiting in adult patients.

GNH USA supplies Kytril as a licensed, GDP‑compliant product to hospitals, oncology centres, and pharmacies worldwide, meeting EU quality standards for injectable antiemetics. The company ensures cold‑chain handling and compliance with international regulatory requirements for injectable medicines. Kytril is marketed in the European Union and is available for procurement by qualified healthcare institutions.

Granisetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting in specific clinical settings.

- Chemotherapy‑induced nausea and vomiting: Provides prophylactic control of acute and delayed nausea and vomiting in adult patients receiving moderately to highly emetogenic chemotherapy regimens. - Postoperative nausea and vomiting: Used to prevent nausea and vomiting associated with general anesthesia and surgical trauma in adult patients undergoing operative procedures.

Granisetron may cause adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or difficulty passing stool. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, including potential QT interval prolongation. - Severe hypotension: marked drop in blood pressure leading to dizziness or fainting.

When prescribing Granisetron, clinicians should consider several precautionary measures to ensure safe use.

- Assess cardiac history: evaluate for pre‑existing arrhythmias or prolonged QT interval. - Monitor electrolytes: correct hypokalemia, hypomagnesemia which can predispose to cardiac events. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concomitant use with other QT‑prolonging agents: increase risk of cardiac arrhythmia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Granisetron can interact with other medicines, influencing its safety profile.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect may increase risk of constipation and QT prolongation. - Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics): combined effect may lead to serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase Granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy of Granisetron. - Opioids: may enhance risk of constipation when combined with Granisetron.